Biotech news on October 20, 2026

1. 0105:31 UTC

   AstraZeneca, Oracle sign non-binding AI deal to boost trial recruitment

   2 outlets · first: Rttnews Clinical trial

   Machine summary AstraZeneca, together with Oracle Health & Life Sciences, announced they have signed a non‑binding term sheet for a worldwide AI collaboration. It targets clinical trial recruitment, on earlier disease diagnosis, on drug safety monitoring and on real‑world evidence. Financial terms were not disclosed. Projects are planned across oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, and rare diseases in the US, Middle East and Europe, starting with hypertension care and clinical research in Abu Dhabi with M42.

   1. AstraZeneca and Oracle Health & Life Sciences said they signed a non-binding term sheet for a global AI collaboration; financial terms were not disclosed, according to the companies.
   2. The specified focus areas include recruiting participants for clinical trials, diagnosing diseases sooner, monitoring drug safety, and applying real-world evidence.
   3. The companies said projects are planned across oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, and rare diseases, in the United States, the Middle East and Europe.
   4. A debut initiative, run alongside the health firm M42 in Abu Dhabi, targets both hypertension treatment and clinical studies; its goals are to spot people whose blood pressure remains uncontrolled and to boost enrollment in trials.
   5. According to the companies, the project will draw on de-identified real-world data, protected by privacy and security safeguards, and AstraZeneca will not be given any patient-identifiable information.

   Reported by Rttnews and Seeking Alpha.

   • AstraZeneca
   • Oracle Health & Life Sciences
   • Real-world evidence
   • M42

2. 0213:27 UTC

   Myriad to sell prenatal testing business to Labcorp for $210M

   2 outlets · first: Seeking Alpha Acquisition

   Machine summary The announced scope covers the Prequel, Foresight, SneakPeek and FirstGene tests. Myriad said in the joint announcement that the sale followed a strategic review process aimed at concentrating its portfolio.

   1. According to a joint announcement issued by Myriad Genetics and Labcorp on October 20, 2026, the two firms have entered a definitive agreement; Myriad will transfer to Labcorp its Prenatal Health testing business.
   2. According to the announcement, the stated consideration came to $210 million cash plus the worth of the Prenatal Health testing business's inventory on closing.
   3. The transaction covers the Prequel, Foresight, SneakPeek and FirstGene tests, the announcement states.
   4. Myriad said the sale is the outcome of what it described as a disciplined strategic review process focused on sharpening its portfolio, according to the joint statement.
   5. The companies said the transaction is intended to benefit patients through expanded access and to support the strategic priorities of both firms, per the announcement.

   Reported by Seeking Alpha and marketnewsdesk.com.

   • Myriad Genetics
   • FirstGene
   • Foresight
   • Labcorp
   • Prequel
   • SneakPeek

3. 0316:06 UTC

   Coverage recordcontractpharma.com: “Hansoh Pharma, Roche Join to Accelerate Global Novel ADC Development”

   2 outlets · first: contractpharma.com Pharma

   The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

   Reported by contractpharma.com and STAT News.

   • Roche

4. 0419:18 UTC

   Planned newborns hepatitis B trial stalls after police seize doses

   2 outlets · first: The Guardian Clinical trial

   Machine summary Police in Guinea-Bissau seized hepatitis B vaccine doses on Monday earmarked for a trial led by researchers, Ars Technica reported. Two people are under investigation by Danish authorities for alleged scientific misconduct, Ars Technica reported.

   1. Police in Guinea-Bissau raided the Danish researchers' offices on Monday and seized hepatitis B vaccine doses intended for a newborns trial, Ars Technica reported.
   2. The CDC announced in December an unsolicited $1.6 million grant to Peter Aaby and Christine Stabell Benn of the Bandim Health Project, according to Ars Technica.
   3. Trial plans were halted in January after international health experts quoted by Ars Technica called the design unethical over the potential exposure of thousands of newborns to hepatitis B.
   4. Guinea-Bissau Health Minister Quinhin Nantote said at a press conference the government had not authorized the trial, per Reuters.

   Reported by Ars Technica and The Guardian.

   • Bandim Health Project
   • hepatitis B vaccine
   • Danish authorities

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.